National Assembly for Wales

Back to Search
WAQ78575 (e) Tabled on 11/07/2019

What consideration has the Welsh Government given to the establishment of a patient access scheme for Liothyronine in Wales?

Answered by Minister for Health and Social Services Answered on 16/07/2019

The Welsh Government has given no consideration to establishing a patient access scheme (PAS) for liothyronine.  

PAS arrangements are made under the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.  A PAS proposes a discount, rebate or other variation from the list price of a branded medicine when it is purchased by the NHS.  Liothyronine is a generic medicine, the price of which is determined by its manufacturer, with the cost of liothyronine to the NHS reflecting the price its manufacturers charge suppliers such as pharmacies. 

Explore the National Assembly for Wales